SEC|cas:1802997-81-4|西域试剂

SEC,98.13%

产品编号：Bellancom-125355| CAS NO：1802997-81-4| 分子式：C₂₂H₂₃ClN₂O₅| 分子量：430.88

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-125355	￥3000.00	杭州北京（现货）
Bellancom-125355	￥5000.00	杭州北京（现货）
Bellancom-125355	￥9500.00	杭州北京（现货）
Bellancom-125355	￥15500.00	杭州北京（现货）
Bellancom-125355	￥22500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

SEC

产品介绍

SEC 通过 AMPK/mTORC1/STAT3 信号通路诱导 ANXA7 GTPase 的激活。SEC 选择性的促进癌细胞的凋亡，诱导 ITGB4 核转位，表达高水平 ITGB4。

生物活性

SEC induces activation of ANXA7 GTPase via the AMPK/mTORC1/STAT3 signaling pathway. SEC selectively promotes apoptosis in cancer cells, expressing a high level of ITGB4 by inducing ITGB4 nuclear translocation.

体外研究

SEC (20 µM) inhibits the cell migration of HEK 293T RKIP^−/− cells and PC3 prostate cancer cells.
SEC (20 µM) significantly increases AMPK phosphorylation in PC3 cells, which is inverted by ANXA7 GTPase specific inhibitor ABO, indicating that activated ANXA7 with enhanced phosphorylation level promotes AMPK phosphorylation (cell selectively).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	HEK293T RKIP^−/− cells.
Concentration:	20 µM.
Incubation Time:	24 h.
Result:	Suppressed HEK293T RKIP^−/− cell migration while had no effect on HEK293T RKIP^+/+ cells.

体内研究
(In Vivo)

SEC (3 mg/kg/day or 18 mg/kg/day) suppresses metastasis in PC-3M-Luc orthotopic implantation nude mice model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Luciferase-labeled PC-3M-Luc cells (2×10⁶ per 50 µL sterile HBSS^−/−) are orthotopically inoculated into the prostates of 8-week-old nude mice.
Dosage:	3 mg/kg/day or 18 mg/kg/day.
Administration:	IP daily for 3 weeks.
Result:	Suppressed the lymph node metastatic capacities of PC-3M-Luc cells in the nude mice model. Decreased the mRNA level of CCL2, APLN and IL6ST in implanted tumors. Did not affect the body weight of the mice.

体内研究

SEC (3 mg/kg/day or 18 mg/kg/day) suppresses metastasis in PC-3M-Luc orthotopic implantation nude mice model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Luciferase-labeled PC-3M-Luc cells (2×10⁶ per 50 µL sterile HBSS^−/−) are orthotopically inoculated into the prostates of 8-week-old nude mice.
Dosage:	3 mg/kg/day or 18 mg/kg/day.
Administration:	IP daily for 3 weeks.
Result:	Suppressed the lymph node metastatic capacities of PC-3M-Luc cells in the nude mice model. Decreased the mRNA level of CCL2, APLN and IL6ST in implanted tumors. Did not affect the body weight of the mice.

体内研究

SEC (3 mg/kg/day or 18 mg/kg/day) suppresses metastasis in PC-3M-Luc orthotopic implantation nude mice model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Luciferase-labeled PC-3M-Luc cells (2×10⁶ per 50 µL sterile HBSS^−/−) are orthotopically inoculated into the prostates of 8-week-old nude mice.
Dosage:	3 mg/kg/day or 18 mg/kg/day.
Administration:	IP daily for 3 weeks.
Result:	Suppressed the lymph node metastatic capacities of PC-3M-Luc cells in the nude mice model. Decreased the mRNA level of CCL2, APLN and IL6ST in implanted tumors. Did not affect the body weight of the mice.

性状

Oil

溶解性数据

In Vitro:

DMSO : 100 mg/mL (232.08 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.3208 mL	11.6042 mL	23.2083 mL
5 mM	0.4642 mL	2.3208 mL	4.6417 mL
10 mM	0.2321 mL	1.1604 mL	2.3208 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (5.80 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.80 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (5.80 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (5.80 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.80 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.80 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。